Armata Pharmaceuticals is a clinical-stage biotechnology enterprise dedicated to discovering, developing, and commercializing novel synthetic bacteriophage therapeutics designed to combat severe, drug-resistant bacterial infections. Leveraging its proprietary phage engineering technology platform, the company targets challenging pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus that frequently cause chronic or life-threatening hospital-acquired infections. By utilizing customized lytic phages that can selectively destroy specific disease-causing bacteria while preserving beneficial microbiome flora, Armata aims to provide alternative precision treatments for patients suffering from antibiotic-resistant conditions.